Drug-drug Interaction Clinical Trial
Official title:
Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban to Improve Rational Pharmacological Care of Patients With Prostate Cancer
Enzalutamide is one of the oncolytic drugs that showed efficacy and safety in most of the features of prostate cancer. Approximately 17% of the patients treated with enzalutamide need pain control. Nearly all opioids are metabolized through one of the CYP enzymes induced by enzalutamide, making optimal pain management difficult. For pain control, while using enzalutamide, morphine is being advised since morphine is mainly glucuronidated by UGT2B7 and to a lesser extent UGT1A1. Enzalutamide is in vitro an inducer of UGT1A1 and may inhibit UGT2B7 which could alter morphine concentrations, though the clinical relevance of this interaction is unknown. In patients with cancer, Direct Oral Anticoagulants (DOACs) are frequently used since vitamin-K antagonists were reported less effective than DOACs in preventing thromboembolic events. However, DOACs are all metabolized through CYP3A4 or P-gp. Due to interaction potential with DOACs, patients treated with enzalutamide are switched to Low Molecular Weight Heparin (LMWHs) administered subcutaneously which is considered safe but less patient friendly. For patients comfort DOACs are preferred over the use of LMWHs. Since rivaroxaban and apixaban are both major substrates for CYP3A4, combination with enzalutamide is prohibited. Dabigatran is a DOAC which is only metabolized by P-gp and edoxaban is a minor substrate for CYP3A4. Therefore, both might be safe to combine with enzalutamide. However, in patients with an active malignancy edoxaban is preferred according to national guidelines. Still, it is unknown if enzalutamide has a significant effect on the edoxaban exposure. The purpose of this study is to evaluate the effect of enzalutamide on morphine and edoxaban pharmacokinetics.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05692570 -
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04328766 -
Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT03990129 -
Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03985969 -
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
|
Phase 1 | |
| Completed |
NCT03302845 -
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02887443 -
A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate
|
Phase 1 | |
| Completed |
NCT01361217 -
The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
|
N/A | |
| Completed |
NCT06066060 -
A DDI Study of JMKX000623 and Metformin Hydrochloride
|
Phase 1 | |
| Completed |
NCT03723395 -
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
|
Phase 1 | |
| Recruiting |
NCT05789173 -
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
|
Early Phase 1 | |
| Completed |
NCT04598542 -
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05044962 -
Kuwa Free! - Live Free!
|
N/A | |
| Completed |
NCT04487145 -
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
|
Phase 4 | |
| Completed |
NCT05108051 -
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
|
Phase 1 | |
| Active, not recruiting |
NCT04669678 -
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
|
Phase 4 | |
| Completed |
NCT01991327 -
Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
|
Phase 1 | |
| Completed |
NCT04218513 -
Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection
|
Phase 1 | |
| Completed |
NCT05492318 -
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
|
Phase 1 | |
| Completed |
NCT01309854 -
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT05306379 -
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
|
Phase 1 |